Cell Line Development Market Poised To Reach $6.24 Billion By 2022: Grand View Research, Inc.

According to a report by Grand View Research, Inc.; the global Cell Line Development Market is projected to reach a valuation of around USD 6.24 billion by 2022. Rising demand for monoclonal antibodies and availability of advanced techniques to develop new cell lines can propel the market during the forecast period (2012 to2022).
Additionally, factors such as growing adoption of regenerative medicine, favorable government efforts and growing expenditure for biotechnology industry can further impel market expansion. Improving healthcare infrastructure and economic development can have positive impact on the market over the forecast period. Apart from that, growing occurrence of autoimmune diseases and cancer can propel the market for cell line development in near future.

Flourishing biopharmaceutical industry is expected to increase the need for cell line development technique in the coming years. Cells can be used as an expansion host for the production of recombinant monoclonal antibodies in various biopharma companies. Growing production of biosimilars owing to patent expiration of branded biologics as well as recombinant proteins is also expected to boost the cell line development market over the forecast period.

Moreover, high prevalence of chronic diseases has increased the need for effective treatment solutions. This is expected to fuel the demand for drugs, vaccines, biosimilars, and therapeutic proteins. The vaccines developed using animal cells are used to treat many conditions such as rotavirus, smallpox, polio, Japanese encephalitis, hepatitis A, varicella, rabies, zoster, and rubella. This is one of the primary drivers for the global market.

Furthermore, ongoing research and development for stable and authentic cell lines and development of technologically advance procedures like micro bioreactor and single use bioreactor for large sized bioproduction can provide lucrative growth opportunities for the market. Rise in biotechnology based applications such as cell culture, gene therapy, and drug discovery can provide significant traction for the global market in near future.

The worldwide cell line development market can be segmented on the basis of product, source, type, and region. Based on type, the market can be fragmented into reagents and media, accessories and consumables, and equipment. As per source, the market can be categorized into mammalian and non-mammalian. Based on type, the market can be classified into hybridomas, recombinant cell lines, continuous cell line, and primary cell lines.

Geographically, the market can be divided into Europe,North America, Asia Pacific, Latin America, Middle East & Africa. In 2014, North America held the largest revenue share owing to high adoption of cell culture techniques, availability of developed infrastructure, supportive government initiatives and high healthcare expenditure. In addition, increasing awareness regarding monoclonal antibodies application in the treatment of cancer and development of innovative procedures for bioproduction are some of the significant factors influencing the regional market. In addition, existence of research organizations like Sigma-Aldrich Corporation, American Type Culture Collection (ATCC), and others that are providing high-quality biologics services can also be attributed towards the regional market growth.

Asia Pacific is likely to exhibit lucrative growth during the forecast period due to growing investment in healthcare infrastructure by government and private sectors. Increasing number of contract research organizations (CROs) providing pertinent services is also anticipated to impel regional market over the forecast period. In addition, increasing research and development (R&D) efforts for the establishment of stable cell lines and growing biologics production can create positive outlook for the market.

The biotechnology industry is expected to grow swiftly in emerging countries over the forecast period. This growth can be accredited to improving healthcare infrastructure and rise in public healthcare programs. For instance, in India, several organizations such as the Department of Biotechnology (DBT), Department of Scientific & Industrial Research (DSIR), and Department of Science and Technology (DST) are regulating the production. These organizations offer guidelines associated with raising funds, making or transferring technology, and creating manpower for the production. Such efforts can boost the market in the region.

Some of the leading companies operating in the cell line development market include Wuxi AppTec Inc.; Corning Inc.; Thermo Fisher Scientific Inc.; and Sigma-Aldrich Corporation. The market is extremely competitive and is expected to witness strategic initiatives like mergers and acquisitions (M&A), partnership agreements, patent registration, and licensing in near future.

Browse Press release of this Report: https://www.grandviewresearch.com/press-release/global-cell-line-development-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

No comments:

Post a Comment

mHealth Apps Market Is Projected To Reach $236.0 Billion By 2026

The global  mHealth apps market  size is expected to reach USD 236.0 billion by 2026, according to a new report by Grand View Research, In...